FDA Advisory Panel Votes on Seven Peptides: The July 2026 Outcomes

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider whether seven peptides should be added to the 503A bulk drug substances list — the list that governs which substances compounding pharmacies may legally prepare for patients. Six of the seven were recommended. One was rejected. This page records the outcomes as reported, and explains the part most coverage skipped: the votes are not the final word.

The vote counts

As reported by trade and general press covering the two-day meeting, the committee's recommendations were:

Note the margins. None of these was a landslide — the closest recommendations passed by two votes, and the single rejection failed by one. That is a committee that was genuinely split.

The unusual part: FDA's own scientists opposed

What made this meeting notable in trade coverage was not the outcome but the split between the advisory committee and the agency's own staff. FDA scientific staff, in their briefing materials and testimony, opposed compounding eligibility for the peptides under review, citing insufficient safety and efficacy evidence. The committee voted the other way on six of seven. It is not unheard of for an advisory committee to diverge from staff review, but it is uncommon enough to be the story.

What a PCAC vote does — and does not — do

• It is advisory, not binding. The FDA makes the final determination through formal rulemaking. The agency has declined to follow advisory committee recommendations before.
• It concerns compounding pharmacies only. The 503A bulks list governs what a licensed compounding pharmacy may prepare under a prescription for an identified patient. It is a separate universe from FDA-approved drugs and from laboratory research chemicals.
• It does not equal approval. A peptide on the 503A list is still not an FDA-approved drug. Approval requires the full new-drug pathway, which none of these seven has completed.
• Nothing changes on the day of the vote. Rulemaking takes time, includes a public comment period, and can end differently from the recommendation.

The three categories worth keeping straight

Coverage of this topic routinely collapses three different things into one word. They are not the same:

1. FDA-approved peptide drugs — fully studied, fully regulated, prescribed as approved products.
2. 503A-compoundable substances — legally preparable by a compounding pharmacy under prescription, but not FDA-approved; evidence quality varies widely. This is the category the July votes concerned.
3. Research-use-only compounds — supplied for in-vitro laboratory work, not for administration to humans or animals, and not part of the compounding pathway at all. This is the category Universe Peptide operates in.

Compounds under review, for laboratory research

Several peptides discussed at the July meeting are supplied by Universe Peptide for in-vitro laboratory research, each with a third-party Certificate of Analysis (COA):

• TB-500 (Thymosin Beta-4) — research grade
• MOTS-c — mitochondrial-derived peptide
• Epithalon (Epitalon) — tetrapeptide
• Semax — ACTH-fragment analogue

Browse the research catalog →

Related reading

• What the FDA 503A bulks list actually is
• What "research use only" actually means
• The July 2026 compounding review, before the vote

Sources & further reading

• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
• STAT News. FDA panel backs compounded BPC-157, KPV peptides. July 23, 2026. statnews.com
• AJMC. FDA Panel Backs 6 Peptides for Compounding. ajmc.com
• Medscape. FDA Expert Panel Backs Compounding of Six Peptides. medscape.com
• CNN. The future of peptides in the US is about to become clearer. July 22, 2026. cnn.com